Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors

Ran He, Gordon Sandford, Gary S. Hayward, William H. Burns, Gary H. Posner, Michael Forman, Ravit Arav-Boger

Research output: Contribution to journalArticlepeer-review

Abstract

Recombinant Towne CMV expressing luciferase under the control of CMV-DNA polymerase (POL) or the late pp28 (UL99) promoters were evaluated for potential application in high-throughput screening of anti-viral compounds. POL-and pp28-luciferase displayed maximal expression 48 and 72 hours post infection, respectively. The pp28-luciferase virus achieved a wider dynamic range of luciferase expression (6-7 logs) and was selected for testing of inhibition by five anti-viral compounds. Luciferase expression highly correlated with plaque reduction and real-time PCR. The pp28-luciferase reporter system is rapid, reproducible, and highly sensitive. It may be applied to screening of novel anti-CMV compounds.

Original languageEnglish (US)
Article number40
JournalVirology Journal
Volume8
DOIs
StatePublished - 2011

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors'. Together they form a unique fingerprint.

Cite this